


**We pioneer
breakthroughs
in healthcare.**

For everyone. Everywhere.



Who we are

€18bn

revenue FY2021¹

>70

countries with direct presence

~66,000

highly skilled employees

22,000+ technical IPRs, thereof
14,000 granted patents

Market leader

in majority of businesses



>90%

of leading hospitals collaborate with us²

>60

AI-supported product offerings

>35%

of revenues based on
innovations introduced in last three years³

>70%

of critical clinical
decisions are influenced by the
type of technology we provide⁴

>600,000

installed base

¹ Revenue FY2021 Siemens Healthineers including Varian's revenue contribution for the period from April 15 to September 30, 2021 |

² Based on hospital rankings in the U.S., China, and Germany | ³ Targeted on a regular basis, 2020 = ~40% | ⁴ AdvaMedDX, "A Policy Primer on Diagnostics"

We are committed to helping fight the world's most threatening diseases.

In 2021, Siemens Healthineers launched **two firsts** into its portfolio in the fight against COVID-19...


FTD SARS-CoV-2 Real-Time PCR Assay¹



For the specific detection of the novel coronavirus causing COVID-19

The new FTD SARS-CoV-2 real time PCR Assay¹ is now available for molecular laboratories. A dual-target design for SARS-CoV-2 identification provides assay robustness and high sensitivity, specificity, and inclusivity.

SARS-CoV-2 Total Antibody Assay¹



Securing communities with science and scale

The SARS-CoV-2 Total Antibody assay¹ detects both IgM and the longer-lasting IgG antibodies in blood to help provide a clearer picture of infection progression. An antibody test can reveal if a person had COVID-19 even if they were asymptomatic or never diagnosed with the disease.

<https://www.siemens-healthineers.com/en-us/clinical-specialities/critical-care>

1. These SARS-CoV-2 molecular and serology tests have not been FDA cleared or approved. These tests have been authorized by FDA under an EUA for use by authorized laboratories. The molecular test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The serology test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens. These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Product availability may vary from country to country and is subject to varying regulatory requirements.

And we are continuing this fight...

Introducing: CLINITEST Rapid COVID-19 Antigen Self-Test



For the moments that matter.

300 million+ CLINITEST COVID-19 tests already acquired outside U.S. and counting...



Product Details¹

- OTC (non-prescription); self-guided; use on asymptomatic individuals
- Qualitative; visually interpreted, no instrument required
- Omicron SARS-CoV-2 variant unlikely to impact performance of CLINITEST Rapid COVID-19 Antigen (Self-)Test²
- Nasal swab samples
- Results in 15 minutes
- 5 tests / box option available for U.S. market initially; 1 test / box option added over time
- Room temperature or refrigerated storage
- 11-month shelf life (from date of original manufacturing)
- 86.5% Sensitivity; 99.3% Specificity
- Dedicated Customer Support Line
- U.S. webpage containing product details and How-To tutorial video; website accessible via QR code printed on outside of test box
- This test is also authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older, or adult-collected anterior nasal (nares) swab samples from individuals aged 2 years or older, with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests.

1. Based on FDA Emergency Use Authorization
2. Based on initial assessment conducted by Siemens Healthineers

CLINITEST Rapid COVID-19 Antigen Self-Test¹



[Click](#) to See How It Works:



3 Reasons Why CLINITEST Rapid COVID-19 Antigen Self-Test ¹

1

Brand

Innovation you can trust, from a brand already relied on globally to support the world's toughest health challenges



2

Quality

Accurate results, test after test:

11-Month Shelf Life¹

86.5% Sensitivity

99.3% Specificity

Omicron SARS-CoV-2 variant unlikely to impact performance¹

300 million+ CLINITEST COVID-19 tests already acquired outside U.S.



3

Supply

Major, Sustained Supply

Tens of millions of tests made available to the U.S. market within weeks of EUA

Major sustained supply available after that

